Dengue is spreading and Sanofi is pulling the market’s only vaccine. What’s next?
PharmaVoice
OCTOBER 23, 2024
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
Understand the 2025-2026 Flu Vaccine Composition Recommendations
Pharmacy Times
APRIL 2, 2025
The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.
Vaccines 
122
122 Vaccines 122
122 Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
BioNTech plots first wave of cancer launches in 2026 as COVID vaccine sales continue to disappoint
Fierce Pharma
MAY 6, 2024
As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey. With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward.
Vaccines 118
118 Vaccines 118
118 
STAT+: CRO claims there was no misconduct in Lyme vaccine trial it ran for Pfizer
STAT
OCTOBER 11, 2023
A company that Pfizer blamed for problems with a clinical trial testing a Lyme vaccine claims that regulators gave its procedures a clean bill of health during a recent inspection. Care Access served as a contract research organization and had enrolled about 3,000 patients in the late-stage trial.
Vaccines 104
104 Vaccines 104
104 
STAT+: Pharmalittle: FDA approves Pfizer’s RSV vaccine for newborns; Boehringer sues over IRA
STAT
AUGUST 22, 2023
The Food and Drug Administration approved a Pfizer vaccine that aims to protect newborns against RSV by vaccinating pregnant people, STAT tells us. The vaccine, marketed as Abrysvo, previously won approval for adults over the age of 60. Continue to STAT+ to read the full story…
Vaccines 84
84 
GSK enters agreement with Canada for influenza vaccines
Pharmaceutical Technology
JULY 18, 2022
GlaxoSmithKline (GSK) has signed an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to aid in protecting adults and children in the country. The company intends to supply both vaccines from its 230,000ft² Sainte-Foy facility in Quebec. .
Vaccines 64
64 
Biovac and IVI enter deal to develop oral cholera vaccine
Pharmaceutical Technology
NOVEMBER 24, 2022
South African bio-pharmaceutical firm Biovac and the International Vaccine Institute (IVI) in South Korea have signed a licencing and technology transfer agreement for developing and manufacturing an oral cholera vaccine (OCV).
Vaccines 59
59 
Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may lead to a Comirnaty monopoly
Pharmaceutical Technology
JUNE 2, 2023
The European Commission (EC) and Pfizer/BioNTech have agreed to amend their current supply contract to deliver Covid-19 vaccines to the EU. More significantly, the revised contract secures about 70 million vaccine doses every year from 2023 to 2026 for member states, leaving little space in the market for competitors.
Vaccines 52
52 Vaccines 52
52 
A roadmap for adopting New Science
pharmaphorum
JUNE 15, 2021
New Science is projected to drive 81% of biopharma revenue growth and 61% of all revenues between 2021 and 2026, outpacing our previous forecast of 54% of all revenues from 2017-2022. And we expect a 69% higher average net present value (NPV) for New Science treatments versus traditional counterparts from 2022—2026.
Vaccines 90
90 Vaccines 90
90 
Five for Friday January 12: Celebrating Success in Advancing Medication Use Quality
PQA
JANUARY 12, 2024
Looking ahead, we are excited to announce dates for the 2024 Leadership Summit, as well as the 2025 and 2026 Annual Meetings. and in 2026, we'll be back in Baltimore. Save the dates for PQA's upcoming major meetings now through 2026! We know you have busy schedules and many meetings to attend throughout the year. Save the Dates!
AstraZeneca plans new US R&D hub as revenues rocket
pharmaphorum
APRIL 29, 2022
The healthy sales increase was bolstered by the timing of orders for AZ’s COVID-19 vaccine Vaxzevria , which made $1.1 “Our combined company has already successfully leveraged internal scientific synergies, and this move will act as a catalyst for even more external collaboration and innovation,” he added.
Vaccines 111
111 Vaccines 111
111 
Industry welcomes boost to health research in UK budget
pharmaphorum
OCTOBER 28, 2021
The Association of the British Pharmaceutical Industry (ABPI) and BioIndustry Association (BIA) both said that the increase acknowledges the enormous contribution made by the life sciences sector in helping to limit the impact of the pandemic through the rapid development of diagnostics, drugs and vaccines.
Vaccines 111
111 Vaccines 111
111 
CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program
The FDA Law Blog
DECEMBER 3, 2023
On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. covered insulin product or vaccine). Manufacturers must sign the agreement by March 1, 2024, to participate in the 2025 plan year.
Labelling 105
105 
Merck obtains favourable US court ruling on sitagliptin patent lawsuit
Pharmaceutical Technology
SEPTEMBER 23, 2022
It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Additionally, Merck has signed patent litigation settlement deals with various generic firms, permitting them to offer generic versions of Januvia and Janumet to the US market in May 2026, or before under specific conditions.
FDA 69
69 
Trends in biopharma contract manufacturing 2022
European Pharmaceutical Review
AUGUST 22, 2022
They noted that while production of COVID-19 pandemic vaccines and therapeutics is currently absorbing much of the flexible capacity available in the industry, but said that as demand moderates, capacity will normalise enabling other products to be prioritised.
Vaccines 98
98 Vaccines 98
98 
Merck defends blockbuster Januvia franchise from patent challenge
pharmaphorum
SEPTEMBER 30, 2022
That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No. Viatris could still take its cases further, but for now Merck has retained market exclusivity for Januvia, Janumet, and Janumet XR until at least 2026. billion in the first half of 2022.
Vaccines 59
59 
Why we need to support healthcare’s vital acceleration
pharmaphorum
JANUARY 29, 2023
Think about recent technological breakthroughs such as mRNA vaccines and the potential for mRNA-based therapeutics, or the recent ramp up in vaccine production facilities – to name just a few examples. That’s what is relentlessly driving industry growth, as well as spurring innovation and efficiency.
Aseptic packaging market to value $35bn by 2033
European Pharmaceutical Review
SEPTEMBER 22, 2023
Aseptic packaging eliminates the necessity for preservatives and refrigeration which is especially advantageous for medications and vaccines that are sensitive to temperature changes. Research Nester highlighted statistics which acknowledged that European production of pharmaceutical aseptic packaging is expected to reach $56 billion by 2026.
Packaging 105
105 
Sanofi claims FDA okay for drug to treat rare blood disorder CAD
pharmaphorum
FEBRUARY 7, 2022
The approval is some relief for Sanofi after a crop of pipeline disappointments last year, with Evaluate estimating the drug could make more than $500 million in sales in 2026. It also abandoned an mRNA-based vaccine for COVID-19 and suffered delays to another COVID-19 shot partnered with GlaxoSmithKline.
FDA 52
52 
Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access
pharmaphorum
JANUARY 21, 2022
And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. There is no easy answer to the question of how to incentivise innovation without restricting access.
Insurance 52
52 
STAT+: Pharmalittle: We’re reading about the U.K. nixing coverage for a cancer drug, sharing bird flu vaccine data, and more
STAT
JULY 30, 2024
… Four pharmaceutical companies involved in the negotiations over prices for Medicare do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs that will take effect in 2026 , Reuters writes.
Vaccines 85
85 
Top 20 Radiopharma Companies Based on Market Cap
PharmaShots
FEBRUARY 21, 2023
threshold by 2026. Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines. With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market.
FDA 56
56 
Meet the 2023 Social Impact Category Winner: Takeda SA
ISPE
SEPTEMBER 29, 2023
For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Takeda has reduced CO2 emission by 861 tons.
How do UK market access prospects look in 2022?
pharmaphorum
FEBRUARY 16, 2022
The Life Sciences Vision also identified seven therapeutic areas that are priorities for the government: treatments for neurodegenerative disorders, cancer immunotherapies, novel vaccines, cardiometabolic therapies, treatments for respiratory disorders, therapies for multi-system ageing and treatments for mental illness.
Elliott fires broadside at GSK in wake of investor update
pharmaphorum
JULY 1, 2021
Along with the appointment of new non-executive directors, Elliott would like to see a moratorium on profit and revenue-related bonuses unless management meets its 2026 targets of 5% profit growth and 10% turnover growth and raising the margin target from 30% to 32%.
Vaccines 52
52 Vaccines 52
52 
Transgene and BioInvent report positive data for oncolytic virus
Pharmaceutical Technology
MAY 25, 2023
Analysis estimates that the oncolytic virus market will reach $1 billion by 2026. Transgene will be presenting new data at ASCO 2023 for its therapeutic cancer vaccines TG4001, in Phase II study in patients with HPV16-positive anogenital tumours ( NCT03260023 ), and TG4050, Phase I study in head and neck cancers ( NCT04183166 ).
US meds spending spiked last year, but will fall quickly
pharmaphorum
APRIL 21, 2022
Overall spending on medicines rose 12% in 2021 to $407 billion, driven by a $29 billion spend on COVID-19 vaccines and medicines. Prescription drug use in the US soared last year, as might be expected during a pandemic, but is expected to fall back sharply in 2023, according to IQVIA’s latest report on the sector.
Vaccines 52
52 Vaccines 52
52 
BioNTech to support trial access for cancer immunotherapies
European Pharmaceutical Review
JULY 6, 2023
Further trials will be launching although most patients are expected to be enrolled from 2026 onwards. The Cancer Vaccine Launch Pad (CVLP), a new partnership led by NHS England, will create a database of eligible NHS cancer patients who will be offered the choice to take part in personalised cancer vaccine trials.
Vaccines 98
98 Vaccines 98
98 
Pharma’s post-pandemic launch performance problem: what’s the prognosis?
pharmaphorum
JUNE 29, 2022
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth.
GSK strikes $3B Shingrix partnership with China powerhouse Zhifei. Is a deal for RSV shot next?
Fierce Pharma
OCTOBER 9, 2023
GSK has forged a partnership with vaccine powerhouse Chongqing | GSK has forged a partnership with vaccine powerhouse Chongqing Zhifei Biological Products to distribute Shingrix in China. billion) for exclusive rights to distribute the shingles shot in China from 2024 through 2026. Zhifei will pay £2.5 billion ($3.05
Vaccines 101
101 Vaccines 101
101 
Five largest chemical and pharmaceutical construction projects initiated globally in Q2 2022
Pharmaceutical Technology
JULY 28, 2022
Tuas Biomedical Park New Vaccine Production Facility – $467m. The project involves the construction of a new vaccine production facilities at Tuas Biomedical Park in Singapore. Construction work started in Q2 2022 and is expected to be completed in Q1 2026. Yeosu Mononitrobenzene Manufacturing Plant – $375m.
Vaccines 52
52 Vaccines 52
52 
Asia Pacific’s five largest chemical and pharmaceutical construction projects that commenced in Q2 2022
Pharmaceutical Technology
JULY 28, 2022
Tuas Biomedical Park New Vaccine Production Facility – $467m. The project involves the construction of a new vaccine production facilities at Tuas Biomedical Park in Singapore. Construction work started in Q2 2022 and is expected to be completed in Q1 2026. Yeosu Mononitrobenzene Manufacturing Plant – $375m.
Vaccines 40
40 Vaccines 40
40 
STAT+: Budget negotiations heat up as ACA subsidy extension, BIOSECURE get dropped
STAT
DECEMBER 10, 2024
Democrats floated the idea of extending the subsidies through 2026 in a year-end deal, and paying for it with a budgetary maneuver that would theoretically extend budget cuts that haven’t actually been implemented, as my colleague Rachel Cohrs Zhang reported. million people would lose coverage annually without the tax credits.
Insurance 98
98 
Landmark Drug Pricing Bill Set to Become Law; HP&M Releases Summary Slide Deck
The FDA Law Blog
AUGUST 14, 2022
The number will begin in 2026 with 10 drug covered under Medicare Part D and will increase annually to 20 Part B and 20 Part D drugs by 2029 and thereafter, with the selected drugs accumulating from year to year. The same will be required under state Medicaid and CHIP programs by October 1, 2023.
Vaccines 98
98 
FDA gives Pfizer’s Group B strep vaccine breakthrough status
pharmaphorum
SEPTEMBER 8, 2022
On the strength of phase 2 data, the FDA has awarded coveted breakthrough status to Pfizer’s vaccine against Group B Streptococcus (GBS), given to expectant mothers to prevent invasive infections in newborns and young infants. The post FDA gives Pfizer’s Group B strep vaccine breakthrough status appeared first on.
Vaccines 52
52 
Nine for 2022: innovation and opportunities in healthcare
pharmaphorum
JANUARY 6, 2022
IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Medicine budget constraint, structural fund largesse.
Vaccines 111
111 
Average cost of Farxiga on Medicare
The Checkup by Singlecare
JUNE 6, 2024
Farxiga was selected as one of the first 10 drugs for negotiated prices and should be available at lower prices starting in 2026. The good news is that all Medicare Part D drug plans offer coverage for at least two drugs within commonly prescribed drug categories.
Insurance 52
52 
Cloud Computing for Pharma: The Road to Digital Transformation
Viseven
SEPTEMBER 18, 2024
The rest is history: vaccines were delivered worldwide in record time, saving millions of lives. By the end of 2026, the company will be able to analyze two million genomes. This quick reporting helped the CDC gather crucial data on the vaccine’s effectiveness, contributing to its further improvements.
Jardiance cost with Medicare
The Checkup by Singlecare
JUNE 6, 2024
That means a new, negotiated price for Jardiance will be effective in 2026. And according to Medicare, negotiated prices will benefit Medicare enrollees in several ways: More vaccines covered – People with Medicare can now receive several vaccines— shingles , whooping cough , and more—at zero cost.
Insurance 52
52 
AZ, Sanofi get first green light for RSV prophylactic antibody
pharmaphorum
NOVEMBER 6, 2022
The new drug will reach the market ahead of RSV vaccines that are designed to protect newborns in the months after birth by vaccinating expectant mothers, who pass on antibodies against the virus in the womb. AZ and Sanofi say they hope to launch the antibody next autumn, in time for the 2023/24 RSV season.
Vaccines 64
64 
Can the Tropical PRV Have Its Moment (Again?) – Not all Priority Review Vouchers are Created Alike: What the Potential Loss of the Rare Pediatric PRV Could Mean for the Tropical Disease PRV Program
The FDA Law Blog
FEBRUARY 4, 2025
With the current lapse in authorization, FDA may only award RPD PRVs for applications that have received an RPD designation before December 20, 2024, andunless reauthorized before thenmay not award any RPD PRVs after September 30, 2026. Below, we discuss some of its downstream impacts on the PRV landscape.
Vaccines 52
52 
Adult data back Merck’s challenger to Pfizer’s blockbuster Prevnar 13
pharmaphorum
OCTOBER 21, 2020
Merck & Co has built more momentum behind its attempt to depose Pfizer’s blockbuster pneumococcal conjugate vaccine Prevnar 13, with two new phase 3 trials backing its rival shot V114. It reiterated its plans to file for approval of the vaccine before the end of the year in the US.
Vaccines 52
52 
How Will the Prescription Drug Provisions in the Inflation Reduction Act Affect Medicare Beneficiaries?
BuzzRx
AUGUST 30, 2022
The Inflation Reduction Act will allow the government to negotiate lower prescription drug costs for some of the highest-priced, covered drugs between 2026 and 2029 and beyond. million who received the shingles vaccine. These are mainly drugs for which generic or biosimilar competitors are not available.
Vaccines 52
52 
Let's personalize your content